Mineralys Therapeutics, Inc. (MLYS) Tops Q4 EPS by 22c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q4 EPS of ($0.61), $0.22 better than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'